- Home
- FC vs TNGX Comparison
FC vs TNGX Comparison
Compare FC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FC
- TNGX
- Stock Information
- Founded
- FC 1983
- TNGX 2014
- Country
- FC United States
- TNGX United States
- Employees
- FC N/A
- TNGX N/A
- Industry
- FC Other Consumer Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- FC Consumer Discretionary
- TNGX Health Care
- Exchange
- FC Nasdaq
- TNGX Nasdaq
- Market Cap
- FC 279.6M
- TNGX 248.2M
- IPO Year
- FC 1992
- TNGX N/A
- Fundamental
- Price
- FC $23.38
- TNGX $2.22
- Analyst Decision
- FC Strong Buy
- TNGX Strong Buy
- Analyst Count
- FC 2
- TNGX 6
- Target Price
- FC $42.50
- TNGX $12.20
- AVG Volume (30 Days)
- FC 77.0K
- TNGX 3.5M
- Earning Date
- FC 06-25-2025
- TNGX 05-12-2025
- Dividend Yield
- FC N/A
- TNGX N/A
- EPS Growth
- FC 8.95
- TNGX N/A
- EPS
- FC 1.34
- TNGX N/A
- Revenue
- FC $286,195,000.00
- TNGX $40,990,000.00
- Revenue This Year
- FC N/A
- TNGX N/A
- Revenue Next Year
- FC $5.25
- TNGX N/A
- P/E Ratio
- FC $17.41
- TNGX N/A
- Revenue Growth
- FC 2.53
- TNGX 10.09
- 52 Week Low
- FC $18.94
- TNGX $1.03
- 52 Week High
- FC $44.46
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- FC 54.57
- TNGX 62.75
- Support Level
- FC $22.65
- TNGX $1.93
- Resistance Level
- FC $23.82
- TNGX $2.67
- Average True Range (ATR)
- FC 0.65
- TNGX 0.40
- MACD
- FC 0.19
- TNGX 0.07
- Stochastic Oscillator
- FC 72.43
- TNGX 59.59
About FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.